1 Validation of multiplex steroid hormone measurements in prostate cancer using

2 plasma for multimodality biomarker studies

- 3 Gido Snaterse^{1,a}, Lisanne F van Dessel^{2,a}, Angela E Taylor³, Jenny A Visser¹, Wiebke Arlt³, Martijn P
- 4 Lolkema², Johannes Hofland^{1,*}
- 5 1. Department of Internal Medicine, Section of Endocrinology, Erasmus MC, University Medical Center
- 6 Rotterdam, Rotterdam, The Netherlands
- 7 2. Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus MC, University Medical
- 8 Center Rotterdam, Rotterdam, The Netherlands
- 9 3. Institute of Metabolism and System Research, University of Birmingham, Birmingham, United
- 10 Kingdom
- ^aThese authors contributed equally to this work.
- 12 *Corresponding author
- 13 Address for correspondence: Johannes Hofland, Department of Internal Medicine, Erasmus MC, Rg5, Dr.
- 14 Molewaterplein 40, 3015 GD, Rotterdam, The Netherlands. Tel.: +31 10 704 0446.
- 15 E-mail: j.hofland@erasmusmc.nl
- 16
- 17 **Running title:** Multiplex steroid measurements in prostate cancer
- 18 Key words: Steroids, Androgens, Testosterone, CellSave, LC-MS/MS
- 19

21 General Abbreviations

- 22 ANOVA Analysis of variance
- 23 CRPC Castration-resistant prostate cancer
- 24 CS CellSave Preservative
- 25 CTC Circulating tumour cell
- 26 ctDNA circulating tumour DNA
- 27 DHEA Dehydroepiandrosterone
- 28 DHT 5α-dihydrotestosterone
- 29 HC Healthy Control
- 30 LC-MS/MS Liquid-chromatography tandem mass spectrometry
- 31 LLOQ Lower limits of quantification
- 32 mCRPC Metastatic castration-resistant prostate cancer
- 33 MS Mass spectrometry
- 34 MSP Mechanically-separated plasma
- 35 MTBE Methyl-tert butyl ether
- 36 PC Prostate cancer
- 37 PBS-BSA phosphate-buffered saline with bovine serum albumin
- 38

40 ABSTRACT

41 Background

- 42 Steroid hormones are essential signalling molecules in prostate cancer (PC). However, many studies
- 43 focusing on liquid biomarkers fail to take the hormonal status of these patients into account. Steroid
- 44 measurements are sensitive to bias caused by matrix effects, thus assessing potential matrix effects is an
- 45 important step in combining circulating tumour DNA analysis with hormone status.

46 Methods

- 47 We investigated the accuracy of multi-steroid hormone profiling in mechanically-separated plasma
- 48 (MSP) samples and in plasma from CellSave Preservative (CS) tubes, that are typically used to obtain
- 49 circulating tumour DNA (ctDNA), compared to measurements in serum. We performed multiplex steroid
- 50 profiling by liquid chromatography-tandem mass spectrometry (LC-MS/MS) in samples obtained from
- 51 ten healthy controls and ten castration-resistant prostate cancer (CRPC) patients.

52 Results

- 53 Steroid measurements were comparable between MSP and serum. A small but consistent decrease of 8
- 54 21% compared to serum was observed when using CS plasma, which was considered to be within the
- acceptable margin. The minimal residual testosterone levels of CRPC patients could be sensitively
- 56 quantified in both MSP and CS samples.

57 Conclusions

58 We validated the use of MSP and CS samples for multi-steroid profiling by LC-MS/MS. The optimised use 59 of these samples in clinical trials will allow us to gain further insight into the steroid metabolism in PC 60 patients.

61 INTRODUCTION

Prostate cancer (PC) is a steroid-hormone dependent disease where and rogens play a pivotal role in the 62 63 evolution of the disease. Targeting the androgen receptor (AR) signalling pathway through androgen 64 deprivation therapy (ADT) in locally advanced and metastatic PC is a highly effective way to inhibit 65 tumour growth¹. However, tumour cells will eventually become resistant to these low androgen 66 concentrations and show disease progression. Resistance mechanisms include AR modifications, like mutations and overexpression^{2,3}, and changes in androgen biosynthesis and metabolism, thereby 67 increasing intratumoural androgen availability⁴⁻⁶. The continued importance of the androgen signalling 68 69 pathway in castration-resistant prostate cancer (CRPC) is underlined by the survival benefits observed 70 with second-line therapies such as the anti-androgen enzalutamide and adrenal steroidogenesis inhibitor abiraterone ⁷⁻¹⁰. Circulating steroid levels are measured to verify efficacy of hormonal 71 treatment and have a prognostic value in patients with PC¹¹⁻¹³. 72

The assessment of circulating steroid hormones relies heavily on sensitive, specific and accurate measurement techniques, especially at castrate levels. Liquid chromatography-tandem mass spectrometry (LC-MS/MS) combines multi-steroid profiling capabilities with superior sensitivity and specificity^{14,15} over older techniques^{16,17}, while maintaining high sample throughput^{18,19}. Multi-steroid assays for LC-MS/MS have been successfully developed in recent years to improve the detection and diagnosis of disorders associated with abnormal steroid hormones concentrations²⁰⁻²³.

Steroid measurements are predominantly performed in serum samples. Previous LC-MS/MS studies have shown that steroids can be quantified reliably across different blood matrices²⁴⁻²⁶, but there are differences observed between plasma and serum, use of glass or plastic tubes in the analytic process, or when using tubes with different stabilizing agents or with gel-separators for blood collection²⁴⁻²⁹.

83 Consequently, alternative collection tubes and extraction methods must be validated before they can84 reliably be used for steroid profiling.

The use of CellSave (CS) Preservative tubes in population- and patient-based cohorts has grown as this specialised 'cell-stabilizing' blood collection tube preserves both circulating tumour cells (CTCs) and cellfree circulating tumour DNA (ctDNA)^{30,31}. These biomarkers allow for the assessment of tumour cell genomic characteristics such as genomic instability in these patients³². These samples are now extensively collected in (cancer) biobanks and could potentially also be used to measure patient steroid profiles.

91 Mechanical blood separation methods are similarly gaining popularity in clinical chemistry due to their 92 easy applicability compared to the use of a separation gel. The BD Vacutainer® Barricor[™] is a 93 mechanically-separated plasma (MSP) tube, and it has shown no obvious bias in steroid hormone 94 measurements versus a gel-based plasma tube in a single study³³, but this was confined to a select 95 number of five steroids, warranting further investigation.

96 In this study, we aimed to determine if plasma obtained with MSP and CS tubes is suitable for multiplex 97 steroid profiling, which, if confirmed, would streamline biomaterial collection for ctDNA and steroid 98 profiling in cancer patients to the use of a single tube. To this end, we performed LC-MS/MS analysis on 99 plasma samples obtained with MSP and CS tubes in comparison to serum obtained with standard SST[™] II 100 Advance Vacutainer[®] tubes, collecting blood from healthy control (HC) subjects and patients with 101 metastatic CRPC (mCRPC).

103 MATERIALS AND METHODS

104 Subjects

105 At the Erasmus MC Cancer Institute in Rotterdam, The Netherlands, healthy controls (HCs) and patients 106 were included within study EMC-2016-761, which was approved by the medical ethical committee of 107 our institute. HCs were all adult male subjects. Patients were adult subjects with mCRPC treated with 108 ADT. Patients were eligible to start treatment with or were currently treated with second-line hormonal 109 therapy (abiraterone with prednisone, enzalutamide or apalutamide). For all subjects the following 110 exclusion criteria were applied: 1) an endocrine disease with altered activity of the hypothalamic-111 pituitary-adrenal or hypothalamic-pituitary-gonadal axis; and 2) the use of medications, excluding those 112 used to treat PC, that interfered with circulating steroid levels or dysregulated the hypothalamic-113 pituitary-adrenal or hypothalamic-pituitary-gonadal axis. All subjects provided written informed consent 114 before any study procedure.

115 Samples

Blood was collected from HCs and mCRPC patients in SST[™] II Advance Vacutainer[®] (serum; BD, Franklin
Lakes, NJ, USA), Vacutainer[®] Barricor[™] (BD) and CellSave Preservative (Menarini Sillicon Biosystems Inc,
Huntington Valley, PA, USA) blood collection tubes. All samples were processed within 96 hours after
blood collection. All tubes were centrifuged at 1,711*g* for 10 minutes at room temperature. Plasma from
CS tubes was subsequently centrifuged at 12,000*g* for 10 minutes at 4°C. Samples were stored at -80°C
until extraction.

122 Steroid extraction

123 Calibration series (0.25 ng/mL – 500 ng/mL for HC, and 0.01 ng/mL – 500 ng/mL for mCRPC) were 124 prepared in phosphate buffered saline (PBS) with 0.1% bovine serum albumin (BSA) or in charcoal-

125 stripped pooled human serum (Goldenwest Diagnostics, Temecula, CA, USA). Steroids investigated were 126 17-hydroxyprogesterone, androstenedione, cortisol, cortisone, corticosterone, dehydroepiandrosterone 127 (DHEA), dihydrotestosterone (DHT) and testosterone. The stripped-serum calibration series was used to 128 quantify all steroids with the exception of androstenedione, due to a high background signal in stripped 129 serum but not in PBS-BSA. An internal standard solution was prepared in methanol/water 50/50 with 130 equal concentrations (1 μ g/mL) of the following deuterated steroids: 17-hydroxyprogesterone-d8, 131 cortisol-d4, corticosterone-d8, DHEA-d6, DHT-d3, testosterone-d3. All steroids were obtained from 132 Sigma Aldrich, UK.

133 400 µL of sample was transferred to hexamethyldisilazane-treated (Thermo Fisher) glass tubes (VWR, 134 Amsterdam, The Netherlands). 20 µL of the internal standard solution was added and all samples were thoroughly vortexed. Liquid-liquid extraction was performed as previously described³⁴ by adding 2 mL 135 136 methyl-tert butyl ether (MTBE, Sigma Aldrich, Zwijndrecht, The Netherlands) to each tube and vortexing. 137 The samples were left at room temperature for 30 minutes to allow phase separation. The upper 138 organic layer was transferred and the MTBE was evaporated under nitrogen at 50° C. The samples 139 underwent a second liquid-liquid extraction with 2 mL MTBE. Samples were reconstituted in 125 µL LC-140 MS grade 50% methanol (CHROMASOLV, Sigma Aldrich, Zwijndrecht, The Netherlands) before 141 measurement.

142 Steroid analysis by tandem mass spectrometry

143 Steroid concentrations were measured by mass spectrometry (Xevo TQ-XS, Waters, Milford, MA, USA) 144 after injection of 20 µL sample volume and separation on an ACQUITY uPLC (Waters) with a Waters HSS T3 column (2.1 mm x 50 mm, 1.8 μ m, Waters)³⁵⁻³⁹. The mobile phases consisted of water (A) and 145 146 methanol (B) both with 0.1% formic acid and a 5-minute linear gradient was used (45 – 75% B) with a 147 flow rate of 0.6 mL/min. The multiple reaction monitoring settings and retention times of the LC-MS/MS method were previously reported^{36,38,39}. The method used represents an optimisation of these methods, 148 149 steroid transitions were re-tuned for optimum response. The updated reaction settings, retention times 150 and lower limits of quantification (LLOQ) can be found in **Supplementary Table 1** and a representative 151 chromatogram can be found in **Supplementary Figure 1**.

Steroids were quantified against the linear calibration series relative to an internal standard and were only included in the final analysis if the calibration series R² was > 0.99 and appropriate lower limits of quantification were reached. The LLOQ was set to the lowest calibration concentration that had a clearly defined peak and a signal-to-noise ratio > 10. Samples with concentrations below the LLOQ were detectable, but quantification was less accurate.

157 Statistics

LC-MS/MS raw data was processed using MassLynx (v4.1, Waters). Statistical analysis was performed using GraphPad Prism (Version 6). Normality of the data was analysed with a D'Agostino & Pearson's test. Comparisons of steroid hormone concentrations between the blood collection tubes were performed with Bland-Altman difference analysis and repeat measurements 1-way ANOVA with posthoc Dunnett's test. Correlations in hormone levels were determined by Deming regression. Group concentrations and differences are shown as mean ± SD, unless specified otherwise. P values were considered significant if <0.05.

165 **RESULTS**

166 **Comparison of blood collection tubes**

167 Baseline characteristics of the study participants are shown in **Table 1**. Circulating steroid levels of 8 168 steroids were determined by LC-MS/MS in plasma collected with CS and MSP tubes, respectively, and 169 serum, all collected from 10 HCs and 10 mCRPC patients. Quantification and concentration ranges for the steroids are reported in **Table 2.** Most steroids could be guantified in HCs at the level of the lowest 170 171 calibration sample (0.25 ng/mL), with the exception of androstenedione (0.5 ng/mL), DHEA (1 ng/mL) 172 and DHT (1 ng/mL). Serum values below the LLOQ were detected for DHEA (HC: n = 1, mCRPC: n = 4), 17-173 hydroxyprogesterone (mCRPC: n = 2) and testosterone (mCRPC: n = 2) and excluded from further 174 analysis.

The values observed in MSP samples were comparable to those found in serum samples for most steroids. The only exception was DHEA, which was higher ($21.3 \% \pm 32.9 \% p < 0.05$) in MSP samples than in serum (**Figure 1**). In CS samples, significantly lower concentrations compared to serum samples were observed for corticosterone (-16.2 % ± 15.2 %, p<0.001), 17-hydroxyprogesterone (-9.4 % ± 19.9 %, p<0.05), cortisol (-13.2 % ± 13.0 %, p<0.001), cortisone (-14.4 % ± 13.1 %, p<0.001), and androstenedione (-18.4 % ± 13.6 %, p<0.001). No significant differences were found for DHEA compared to serum.

Similar steroid concentrations between HC and mCRPC subjects were observed for corticosterone, cortisol and cortisone (**Figure 2**). Lower concentrations were observed for 17-hydroxyprogesterone, androstenedione, DHEA and testosterone in mCRPC subjects. This was likely due to a combination of castration (testosterone) and age-related effects, as the mCRPC subjects were older than the healthy control subjects.

187 Circulating androgen concentration in mCRPC patients are >10 fold lower than in healthy men due to 188 ADT, requiring highly sensitive techniques to accurately measure residual androgens. Therefore, the 189 calibration series was expanded to include lower concentrations (0.01 - 0.25 ng/mL) to allow quantification of castrate testosterone levels. Accurate quantification at low concentration was 190 191 achieved, with an analytic LLOQ for testosterone of 0.1 nmol/L. Similar to the other steroids, lower 192 testosterone concentrations compared to serum were detected in CS samples, but not in MSP samples, 193 at normal HC concentrations (-11.5 % \pm 2.8 %, p<0.001) and at castrate concentrations (-16.9 % \pm 24.3 %, 194 p<0.05) (Figure 1). Low signal-to-noise ratios limited the reliability of DHT quantification which could not 195 be accurately quantified in the mCRPC subjects with our assay.

196 Correlation of steroid measurements between matrices

197 The correlations between results obtained in MSP and CS samples compared to those results obtained in serum were independently determined by Deming regression (Figure 3). For DHT analysis only HC 198 199 samples were included. Corticosterone, DHEA and testosterone were normally distributed after log-200 transformation. Significant correlations (all p<0.001) between both matrices and serum was observed for 17-hydroxyprogesterone, androstenedione, corticosterone, cortisol, cortisone, DHEA and 201 testosterone. The analysis also revealed a poor correlation for DHT between CS and serum ($R^2 = 0.60$) 202 and between MSP and serum ($R^2 = 0.45$), whereas steroid concentrations measured in MSP and CS 203 samples, respectively, correlated more closely ($R^2 = 0.89$, y = 0.89x + 0.15) (data not shown). 204

206 **DISCUSSION**

207 In this study, we investigated whether MSP- or CS-derived plasma, samples that are abundantly present 208 in biobanks obtained from PC patients, are suitable for multiplex steroid profiling by LC-MS/MS. We 209 compared them to the current standard collection method using serum samples collected with SST™ II Advance Vacutainers[®]. We showed that measurements in MSP are equal to serum. When collecting 210 plasma in CS tubes, steroid concentrations were 8-21% lower than measurements using serum or MSP. 211 212 The Guideline on Bioanalytical Method Validation (2011) of the European Medicines Agency advises that 213 accuracy must be within 15 % of the nominal concentration and within 20 % at the $LLOQ^{40}$. The 214 decreases observed for most steroids in CS plasma, using serum as a reference, were within this 215 acceptable range (Table 2). Therefore, we conclude that CS plasma samples are suitable for steroid 216 profiling, which can be combined with analysis of CTCs or ctDNA. However, caution is advised when 217 interpreting results obtained in CS plasma samples against reference values that were obtained in 218 serum, and direct comparison to samples collected in other tubes should be avoided. Nevertheless, 219 these findings may reduce patient burden and open up the possibility to undertake detailed steroid 220 profiling of large collections of biomaterial already collected for ctDNA analysis.

221 In this study, most steroids could be quantified accurately within the range of the calibration series. 222 Most of the Δ 4-steroids, such as cortisol or testosterone, ionise more easily and so can be accurately quantified at low levels (0.03 - 0.15 nM). This allows for the quantification of testosterone in mCRPC 223 patients (typically <0.5nM)¹¹. Δ 5-steroids such as DHEA and saturated steroids such as DHT are poor 224 ionisers and quantification at lower concentrations is beyond the sensitivity of the mass spectrometer²². 225 226 Like testosterone, DHT levels are suppressed in castrated patients and the concentrations in these 227 patients could not be accurately assessed. DHEA levels in men decline with age⁴¹, and the mCRPC 228 subjects in this study were older than the HC subjects. Consequently, values below the LLOQ were

detected in four mCRPC patients and were excluded from the analysis. Derivatization, for example to form an oxime, increases ionisability, and therefore sensitivity allowing low level quantification of $\Delta 5$ and 5α -reduced steroids²². However, the derivatization method is not suited for routine clinical diagnostic measurements due to increased sample preparation time and cost. In addition to this, fragmentation produces multiple derivatives for some steroids adding to the complexity of the analysis.

234 Matrix effects and cross-reactivity are established sources of interference in steroid hormone profile studies with immunoassay and LC-MS/MS²⁴⁻²⁹. Previous studies have identified the type of blood sample 235 236 tube as a potential source of interference. MSP tubes like BD Vacutainer® Barricor™ utilise mechanical 237 separation of plasma, which makes them easily applicable, but the accuracy of steroid hormone 238 measurements in these tubes has not been fully validated yet. Our study shows that multiplex steroid 239 quantification in MSP samples is comparable to the serum collected with the reference tube, in line with a previous study that detected no bias versus gel-based plasma tubes using an immunoassay platform³³. 240 241 The only significant difference between steroid measurements in MSP and serum related to DHEA. 242 Quantification of DHEA at low concentrations with LC-MS/MS remains a challenge as its structure contributes to poor MS ionisation^{22,42}. This challenge could be overcome by using a more sensitive mass 243 244 spectrometer or with the use of derivatization. Prior to using MSP tubes for clinical studies, however, full 245 validation considering accuracy, precision and recovery with larger sample size is recommended.

CS tubes are optimised for the measurement of circulating nucleic acids or tumour cells^{30,31}. The use of this matrix for liquid biopsies has increased exponentially over the last years due to the successful genomic characterization of CTCs or free circulating nucleic acids, but no studies have investigated if plasma from CS tubes are suitable for quantification of circulating steroid hormone levels. Our experiments indicate that steroid measurements in CS samples are affected by a mild bias, which resulted in an approximate 8 – 21% decrease compared to serum. We observed similar effects in both

HCs and mCRPC subjects. CS tubes contain 300 μ L of Na₂EDTA anticoagulant as well as an undisclosed preservative to stabilise cells in the sample. Due to the presence of the Na₂EDTA there may be an inherent dilution of the sample, which amounts to approximately 3-4 % on a 7.5 – 10 mL volume. This dilution factor is insufficient to account for the difference in circulating steroid hormone levels however, and it is possible that other factors also contribute towards the observed difference.

This decrease was observed across a variety of different polarity steroids with different molecular weights. It is therefore unlikely that the preservative co-elutes with one of the steroids and suppresses the MS signal. Either there is an unidentified contaminant in the tubes which affects all steroids or the steroids themselves are being retained/bound to the tube itself. Steroids have been long recognised to bind to plastics⁴³, which may contribute to the lower values in the CS samples.

262 Currently, CS tubes are most commonly utilised in oncological studies to obtain CTCs and ctDNA. 263 Hormonal treatment options in breast- and prostate cancer involve potent suppression of oestrogens or 264 androgens. For example, inhibition of testicular steroidogenesis by ADT will typically lower testosterone levels by >90 $\%^{11}$. Interpretation of such changes is unlikely to be affected by the difference observed in 265 266 CS samples. Especially within the context of a single study the relative difference should affect all 267 samples identically as long as a single collection tube is used. As such, the observed difference is 268 acceptable for most clinical purposes, including the use of CS samples for steroid profiling in PC patients. 269 Steroid profiles and analysis of CTCs or ctDNA investigation will decrease costs and reduce patient 270 burden.

271 In conclusion, MSP samples are suitable for steroid quantification, including castrate range of 272 androgens. Similarly, CS samples are suitable for steroid measurements, although there is a consistent 273 bias of 8 - 21% lower steroid hormone levels. Therefore, all samples in a research study should be

274 collected in the same sample tubes to avoid potential variation due to effects from the tubes

275 themselves.

277 References

2781.Sharifi N, Gulley JL, Dahut WL. Androgen deprivation therapy for prostate cancer. JAMA2792005;294:238-44.

280 2. Linja MJ, Savinainen KJ, Saramaki OR, Tammela TL, Vessella RL, Visakorpi T. Amplification and 281 overexpression of androgen receptor gene in hormone-refractory prostate cancer. Cancer Res 282 2001;61:3550-5.

283 3. Taylor BS, Schultz N, Hieronymus H, et al. Integrative genomic profiling of human prostate 284 cancer. Cancer Cell 2010;18:11-22.

- 2854.Stanbrough M, Bubley GJ, Ross K, et al. Increased expression of genes converting adrenal286androgens to testosterone in androgen-independent prostate cancer. Cancer Res 2006;66:2815-25.
- 5. Montgomery RB, Mostaghel EA, Vessella R, et al. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res 2008;68:4447-54.
- 290 6. Mohler JL, Gregory CW, Ford OH, 3rd, et al. The androgen axis in recurrent prostate cancer. Clin 291 Cancer Res 2004;10:440-8.
- 292 7. Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after 293 chemotherapy. N Engl J Med 2012;367:1187-97.
- 294 8. de Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic 295 prostate cancer. N Engl J Med 2011;364:1995-2005.
- Pizazi K, Tran N, Fein L, et al. Abiraterone plus Prednisone in Metastatic, Castration-Sensitive
 Prostate Cancer. N Engl J Med 2017;377:352-60.
- 29810.Davis ID, Martin AJ, Stockler MR, et al. Enzalutamide with Standard First-Line Therapy in299Metastatic Prostate Cancer. N Engl J Med 2019;381:121-31.
- 30011.Snaterse G, Visser JA, Arlt W, Hofland J. Circulating steroid hormone variations throughout301different stages of prostate cancer. Endocr Relat Cancer 2017;24:R403-R20.
- Sakamoto S, Maimaiti M, Xu M, et al. Higher Serum Testosterone Levels Associated with
 Favorable Prognosis in Enzalutamide- and Abiraterone-Treated Castration-Resistant Prostate Cancer. J
 Clin Med 2019;8.
- 30513.Attard G, Reid AH, A'Hern R, et al. Selective inhibition of CYP17 with abiraterone acetate is306highly active in the treatment of castration-resistant prostate cancer. J Clin Oncol 2009;27:3742-8.
- Wang C, Catlin DH, Demers LM, Starcevic B, Swerdloff RS. Measurement of total serum
 testosterone in adult men: comparison of current laboratory methods versus liquid chromatography tandem mass spectrometry. J Clin Endocrinol Metab 2004;89:534-43.
- Taieb J, Mathian B, Millot F, et al. Testosterone measured by 10 immunoassays and by isotope dilution gas chromatography-mass spectrometry in sera from 116 men, women, and children. Clin Chem
 2003;49:1381-95.
- 16. Handelsman DJ, Newman JD, Jimenez M, McLachlan R, Sartorius G, Jones GR. Performance of direct estradiol immunoassays with human male serum samples. Clin Chem 2014;60:510-7.
- 17. Krasowski MD, Drees D, Morris CS, Maakestad J, Blau JL, Ekins S. Cross-reactivity of steroid
 hormone immunoassays: clinical significance and two-dimensional molecular similarity prediction. BMC
 Clin Pathol 2014;14:33.
- Taylor AE, Keevil B, Huhtaniemi IT. Mass spectrometry and immunoassay: how to measure
 steroid hormones today and tomorrow. Eur J Endocrinol 2015;173:D1-12.
- 19. Monaghan PJ, Keevil BG, Trainer PJ. The use of mass spectrometry to improve the diagnosis and the management of the HPA axis. Rev Endocr Metab Disord 2013;14:143-57.

20. Arlt W, Lang K, Sitch AJ, et al. Steroid metabolome analysis reveals prevalent glucocorticoid excess in primary aldosteronism. JCl Insight 2017;2.

Arlt W, Biehl M, Taylor AE, et al. Urine steroid metabolomics as a biomarker tool for detecting
 malignancy in adrenal tumors. J Clin Endocrinol Metab 2011;96:3775-84.

Hakkinen MR, Murtola T, Voutilainen R, et al. Simultaneous analysis by LC-MS/MS of 22
ketosteroids with hydroxylamine derivatization and underivatized estradiol from human plasma, serum
and prostate tissue. J Pharm Biomed Anal 2019;164:642-52.

22. Storbeck KH, Schiffer L, Baranowski ES, et al. Steroid metabolome analysis in disorders of adrenal steroid biosynthesis and metabolism. Endocr Rev 2019.

Coburn SB, Stanczyk FZ, Falk RT, et al. Comparability of serum, plasma, and urinary estrogen and
 estrogen metabolite measurements by sex and menopausal status. Cancer Causes Control 2019;30:75 86.

Hepburn S, Wright MJ, Boyder C, et al. Sex steroid hormone stability in serum tubes with and
 without separator gels. Clin Chem Lab Med 2016;54:1451-9.

33626.Raff H, Sluss PM. Pre-analytical issues for testosterone and estradiol assays. Steroids3372008;73:1297-304.

- 338 27. Morovat A, James TS, Cox SD, et al. Comparison of Bayer Advia Centaur immunoassay results
 339 obtained on samples collected in four different Becton Dickinson Vacutainer tubes. Ann Clin Biochem
 340 2006;43:481-7.
- 341 28. Smets EM, Dijkstra-Lagemaat JE, Blankenstein MA. Influence of blood collection in plastic vs.
 342 glass evacuated serum-separator tubes on hormone and tumour marker levels. Clin Chem Lab Med
 343 2004;42:435-9.
- 29. Schouwers S, Brandt I, Willemse J, et al. Influence of separator gel in Sarstedt S-Monovette(R) serum tubes on various therapeutic drugs, hormones, and proteins. Clin Chim Acta 2012;413:100-4.
- 346 30. Rothwell DG, Smith N, Morris D, et al. Genetic profiling of tumours using both circulating free 347 DNA and circulating tumour cells isolated from the same preserved whole blood sample. Mol Oncol 348 2016;10:566-74.
- 349 31. van Dessel LF, Beije N, Helmijr JC, et al. Application of circulating tumor DNA in prospective
 350 clinical oncology trials standardization of preanalytical conditions. Mol Oncol 2017;11:295-304.
- 32. van Dessel LF, van Riet J, Smits M, et al. The genomic landscape of metastatic castrationresistant prostate cancers reveals multiple distinct genotypes with potential clinical impact. Nat Commun 2019;10:5251.
- 354 33. Fournier JE, Northrup V, Clark C, et al. Evaluation of BD Vacutainer(R) Barricor blood collection
 355 tubes for routine chemistry testing on a Roche Cobas(R) 8000 Platform. Clin Biochem 2018;58:94-9.
- 356 34. O'Reilly MW, Taylor AE, Crabtree NJ, et al. Hyperandrogenemia predicts metabolic phenotype in
 polycystic ovary syndrome: the utility of serum androstenedione. J Clin Endocrinol Metab 2014;99:1027 358 36.
- 35935.O'Reilly MW, Kempegowda P, Jenkinson C, et al. 11-Oxygenated C19 Steroids Are the360Predominant Androgens in Polycystic Ovary Syndrome. J Clin Endocrinol Metab 2017;102:840-8.
- 36. Quanson JL, Stander MA, Pretorius E, Jenkinson C, Taylor AE, Storbeck KH. High-throughput
 analysis of 19 endogenous androgenic steroids by ultra-performance convergence chromatography
 tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2016;1031:131-8.
- 364 37. van der Pas R, Hofland LJ, Hofland J, et al. Fluconazole inhibits human adrenocortical 365 steroidogenesis in vitro. J Endocrinol 2012;215:403-12.

366 38. Prete A, Taylor AE, Bancos I, et al. Prevention of Adrenal Crisis: Cortisol Responses to Major
 367 Stress Compared to Stress Dose Hydrocortisone Delivery. J Clin Endocrinol Metab 2020;105.

368 39. Juhlen R, Idkowiak J, Taylor AE, et al. Role of ALADIN in human adrenocortical cells for oxidative 369 stress response and steroidogenesis. PLoS One 2015;10:e0124582.

40. Agency EM. Guideline on Bioanalytical Method Validation. 2011.

41. Kaufman JM, Vermeulen A. The decline of androgen levels in elderly men and its clinical and therapeutic implications. Endocr Rev 2005;26:833-76.

- 42. Keski-Rahkonen P, Huhtinen K, Poutanen M, Auriola S. Fast and sensitive liquid chromatography-
- 374 mass spectrometry assay for seven androgenic and progestagenic steroids in human serum. J Steroid
- 375 Biochem Mol Biol 2011;127:396-404.
- 43. Bruning PF, Jonker KM, Boerema-Baan AW. Adsorption of steroid hormones by plastic tubing. J
- 377 Steroid Biochem 1981;14:553-5.

378

380 Acknowledgements

- Funding for this project was provided by the Daniel den Hoed foundation.
- 382 The authors thank the volunteers and patients who made this study possible.

383 Author Information

384 These authors contributed equally: Gido Snaterse and Lisanne F van Dessel.

385 Author Contributions

- 386 G.S. performed the LC-MS/MS experiments, data analysis, prepared figures/tables and wrote the
- 387 manuscript. L.F.D. collected the patient samples, performed data analysis, prepared figures/tables and
- 388 wrote the manuscript. A.E.T. oversaw the LC-MS/MS experiments and analysis of the data, and critical
- revision of the manuscript. W.A. was involved in interpretation of the data and critical revision of the
- 390 manuscript. M.P.L. was involved in the design of the work, collection of the samples and critical revision
- of the manuscript. J.A.V and J.H. were involved in the design of the work, interpretation of the data, and
- 392 critical revision of the manuscript.
- 393 All authors reviewed and approved the final version of the manuscript.

394 **Corresponding author**

395 Correspondence to Johannes Hofland.

396 **Conflict of Interest**

397 M.P.L. is the recipient of grants of Sanofi, Johnson & Johnson and Astellas. Other authors did not declare
398 a conflict of interests.

399 Data Availability

- 400 The datasets generated during and/or analysed during the current study are available from the
- 401 corresponding author on reasonable request.

403 Table 1 – Characteristics of HCs and mCRPC patients

404 *Abbreviations*: HCs - healthy controls, mCRPC – metastatic castration-resistant prostate cancer

	HCs	mCRPC patients	
N	10	10	
Age (median (range))	32 (25 - 56)	64 (59 - 76)	
Androgen Deprivation Therapy (n)		10	
Leuproreline		4	
Gosereline		4	
Bilateral orchiectomy		2	
Current second-line treatment (n)		6	
Enzalutamide		3	
Apalutamide		1	
Abiraterone + Prednisone		1	
Prednisone		1	

406 **Table 2 – Relative differences in CS and MSP samples compared to serum samples.**

- 407 Relative differences are shown as mean ± SD. Statistical comparison was performed by repeated
- 408 measurement 1-way ANOVA with post-hoc Dunnett's Test. *p<0.05, ** p<0.01, ***p<0.001.
- 409 Abbreviations: CS CellSave Preservative, DHEA dehydroepiandrosterone, DHT 5α -
- 410 dihydrotestosterone, HC Healthy Control, mCRPC metastatic castration-resistant prostate cancer,
- 411 MSP mechanically separated plasma

	Healthy			mCRPC		
	Controls (n = 10)		(n = 10)			
	Serum	CS	MSP	Serum	CS	MSP
	Range	Rel. Difference	Rel. Difference	Range	Rel. Difference	Rel. Difference
	nmol/L	mean (SD) %	mean (SD) %	nmol/L	mean (SD) %	mean (SD) %
Corticosterone	2.32 - 32.71	-20.08 (16.6) **	2.6 (11)	0.55 - 25.34	-12.3 (13.3) *	-2.8 (9.8)
17-hydroxyprogesterone	0.37 - 3.75	-14.4 (15.3) *	3.16 (16.26)	0.1 - 1.75	-3.2(24.1)	-2.2 (9.4)
Cortisol	149.1 - 475.7	-13.7 (6.1) ***	-0.14 (3.5)	7.43 - 504.6	-12.7 (17.9) **	-1.3 (16.1)
Cortisone	36.35 - 79.4	-10.8 (6.3) ***	-2 (9.2)	0.1 - 80.81	-17.9 (17.2) **	-1.5 (10.5)
DHEA	0.69 - 36.14	-0.17 (18.8)	28.7 (46.6)*	<loq -="" 1.7<="" td=""><td>-17.7 (16.5)</td><td>6.0 (12.2)</td></loq>	-17.7 (16.5)	6.0 (12.2)
Androstenedione	2.33 - 6.05	-15.85 (13.5) **	6.9 (9.5)	0.48 - 3.19	- 21.2 (14.01) **	6.34 (10.4)
Testosterone	7.47 - 17.74	-11.48 (2.8) ***	0.82 (4.7)	0.13 - 0.78	-16.9 (24.3) *	-2.8 (30.6)
DHT	0.66 - 1.64	-11.26 (29.2)	-3.5 (30.4)	<loq< td=""><td><loq< td=""><td><loq< td=""></loq<></td></loq<></td></loq<>	<loq< td=""><td><loq< td=""></loq<></td></loq<>	<loq< td=""></loq<>

413 Figure 1. CS and MSP samples compared to serum samples in healthy controls and mCRPC patients.

- 414 Steroid concentrations from serum, CS and MSP samples obtained from ten HCs and ten mCRPC patients
- 415 measured by LC-MS/MS. Bland-Altman plots show the relative difference of CS (black) and MSP (gray)
- 416 measurements compared to serum. Continuous lines show the mean difference and dotted lines show
- 417 the upper- and lower limits of the 95% confidence interval.
- 418 Abbreviations: CS CellSave Preservative, DHEA dehydroepiandrosterone, HC Healthy Control,
- 419 mCRPC metastatic castration-resistant prostate cancer, MSP mechanically seperated plasma

420

421 Figure 2 – Circulating steroid concentrations in serum of HCs and mCRPC subjects.

- 422 Steroid hormone concentrations in healthy controls (n = 10) and mCRPC patients (n = 10). Four patients
- 423 received no additional treatment, four received antiandrogens (enzalutamide (n=3) or apalutamide
- 424 (n=1)), one received abiraterone and prednisone and one received prednisone. Line and error represent

425 mean ± SEMs.

- 426 *Abbreviations*: 170HP 17-hydroxyprogesterone, A4 androstenedione, B corticosterone, DHEA –
- 427 dehydroepiandrosterone, mCRPC metastatic castration-resistant prostate cancer, E cortisone, F –
- 428 cortisol, T testosterone

430 Figure 3 – Correlations between CS samples and MSP samples with serum samples.

Deming regression analysis between measurements from serum and CS samples and between serum and MSP samples in HC and mCRPC patients combined. Corticosterone, DHEA and testosterone values did not pass normality testing (D'Agostino and Pearson), but did so after logarithmic transformation. Regression equations for testosterone are presented separately for HCs and mCRPC patients due to the bimodal distribution resulting from ADT. For DHT, only HC values were used as values in CRPC patients were below the LLOQ.

437 *Abbreviations*: ADT – androgen deprivation therapy, CS – CellSave Preservative, DHEA – 438 dehydroepiandrosterone, DHT – Dihydrotestosterone, HC – healthy controls, LLOQ – lower limit of 439 quantification, mCRPC – metastatic castration-resistant prostate cancer, MSP – mechanically separated 440 plasma.





